Expert Interviews

Christopher Bunick, MD, PhD, and Chinweike Ukomadu, MD, PhD, discuss late-breaking phase 3 findings at AAD highlighting high rates of clearance and favorable safety with once-daily oral zasocitinib.

At AAD 2026, Todd Schlesinger, MD, highlighted how staging frameworks and clinicopathologic features can inform treatment decisions in nonmelanoma skin cancer.

Dermatologists tailor seborrheic dermatitis care with shared decisions, steroid-sparing options, combo therapy, and flare-ready expectations.

At AAD 2026, Christopher Bunick, MD, PhD, and Reid Waldman, MD, discuss investigational VDPHL01, extended-release oral minoxidil, for the treatment of women and men with pattern hair loss.

New sunscreen filters, AI tools, and immunotherapies are reshaping skin cancer prevention and treatment, improving precision and long-term survival.

At AAD 2026, Helen He, MD, highlights how minimally invasive molecular profiling distinguishes photoexposed and photoprotected aging trajectories.

At AAD 2026, Melinda Gooderham, MSc, MD, FRCPC, reviewed late-breaking zasocitinib data for psoriasis, noting that 70% of patients reached sPGA 0/1.

Christopher Bunick, MD, PhD, and Kristian Reich, MD, PhD, discuss the long-term efficacy of sonelokimab, with more than 60% of patients achieving HiSCR75 and approximately 30% reaching HiSCR100.

At AAD 2026, Christopher Bunick, MD, PhD, and Patrick Burnett, MD, PhD, discuss late-breaking data of roflumilast cream's improvements in infants with AD.

Pelage’s PP405 novel topical reawakens dormant follicle stem cells, showing signs of terminal regrowth and fueling late-stage alopecia research.

Late-breaking phase 2 findings presented at AAD show nemolizumab achieved high EASI-90 rates and rapid itch relief in pediatric patients with atopic dermatitis.

Nicole Negbenebor, MD, highlights the clinical and professional impact of community-driven education and evidence-based focus in skin of color dermatology.

Christopher Bunick, MD, PhD, interviews medical student Sabine Obagi on the value of conference participation, mentorship, and early exposure for aspiring dermatology clinicians at AAD 2026.

Melanoma cases keep rising, but AI-aided screening, gene profiling, and newer immunotherapies boost early diagnosis and long-term survival, according to Darrell Rigel, MD, MS.

In the final episode, the panel pulls together the clinical “bottom line” from the phase 3 povorcitinib data for hidradenitis suppurativa (HS).

Dermatologists spot hidradenitis suppurativa early, explain it’s inflammatory, and start medical-surgical care and biologics to prevent lasting damage.

Learn how clinicians spot hidradenitis suppurativa early—recurring abscesses, bridging comedones, atypical sites, and when MRI helps distinguish Crohn’s.

In this episode, our panel delves into the safety and tolerability of povorcitinib, specifically addressing the concerns clinicians often face regarding the JAK inhibitor class.

Guardrails and disclaimers are essential for responsible AI deployment in dermatology, according to Faranak Kamangar, MD.

Who is a woman who has shaped your life and career in dermatology? Hear stories from our experts as we celebrate Women's History Month 2026.

Linda Stein Gold, MD, FAAD, shares her thoughts on FDA-approved, once-daily oral icotrokinra for teens and adults with moderate to severe plaque psoriasis, promising biologic-like results, strong safety, and earlier systemic escalation.

PANP360 Immersive will deliver one-day, high-yield dermatology CME for NPs and PAs, featuring hands-on workshops, complex case strategies, and practical tips to optimize therapies.

Explore innovative strategies for treating psoriasis, emphasizing patient communication and evolving treatment goals for better outcomes.

Dermatologists weigh rifamylast, JAK inhibitors and antifungals for long-term seborrheic dermatitis control, balancing efficacy, safety and access.

New rifamilast 0.3% foam shows fast, sustained seborrheic dermatitis clearing with high tolerability—plus tips for long-term maintenance.

Healthcare professionals discuss the balance between patient satisfaction and clinical goals, emphasizing the importance of individualized treatment approaches.

Only 15–20% of eligible patients currently receive systemic psoriasis treatment, and specialists believe icotrokinra's simplicity could meaningfully move that needle.

Dr. Madigan highlights the evolving treatment landscape by discussing promising clinical trial data for second-generation KIT inhibitors, like bezaclastinib and elenestinib, which offer high selectivity and limited CNS penetration. She reinforces the "practice pearl" that nearly all adults with fixed skin lesions have systemic disease, emphasizing that these lesions are distinct from transient hives and require lifelong vigilance.

When used thoughtfully, Faranak Kamangar, MD, says AI can transform generic processes into innovative, time-saving clinical tools.

In this episode, the expert dermatologists explore the quality-of-life outcomes from the STOP HS trials, emphasizing that for patients, the biggest wins are often less pain and less drainage, outcomes not fully captured by HiSCR.